New research suggests that higher global temperatures could have prompted an adaptation in Candida auris, allowing it to infect warm-blooded mammals.
Browsing: Fungal > Candidiasis
Results from the Centers for Disease Control and Prevention has provided insights into why Candida auris outbreaks frequent in healthcare facilities.
Researchers have discovered Candida albicans can cross the blood–brain barrier, triggering an immune response that results in the formation of granuloma-type structures and memory impairments.
Researchers have successfully used monoclonal antibodies to protect animal models from Candida infections for the first time, demonstrating their potential for treating this fungal disease.
We look at some of the highlights of our Twitter chat (#TalkFungi), where we questioned Ilan Schwartz, Andrej Spec, Rebecca Drummond and Jessie Uehling about all things mycology.
In this interview, we speak to Ana Litvintseva, a Medical Mycologist and Team Lead at the Centers for Disease Control and Prevention (CDC; GA, USA) about Candida auris, its emergence and the challenges it presents.
Multi-use patient equipment, such as thermometers, has been linked to one of the largest outbreaks of the emerging drug-resistant fungal pathogen Candida auris to-date.
Results from the Phase II STRIVE trial demonstrates favorable safety, tolerability and efficacy of the antifungal drug, rezafungin.
To round up 2017, we asked our Expert panel to choose their top papers from the year. Here, you can discover these articles and the reasons why they were chosen.
This study looks at Candida tropicalis, evaluating if radiation used in radiotherapy can cause changes in the virulence potential.